BAFF CAR-T cells for relapsed or refractory lymphoma and multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new treatment called BAFF CAR-T cells (LMY-920) for people with certain types of lymphoma or multiple myeloma that have come back or not responded to previous treatments. The therapy uses your own immune cells, modified to attack cancer cells, and may offer a new option when standard treatments have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of B-cell lymphoma (like diffuse large B-cell, follicular, mantle cell, or others) that has returned after at least 2 prior treatments, or that did not respond to your last chemotherapy.
- Or you have multiple myeloma that has returned or not responded after at least 3 prior treatments (including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody).
- You are 18 years or older.
- You are generally able to care for yourself (ECOG performance status of 0, 1, or 2).
- You have at least one measurable tumor or lesion.
- You do not have lymphoma or leukemia that has spread to the brain or spinal cord.
- You have adequate organ function (heart, lungs, liver, kidneys).
- If you are of childbearing potential, you agree to use effective birth control for at least 6 months after the infusion.
- You have not had certain types of transplants or have no active graft-versus-host disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy (LMY-922) that targets BAFF in people with certain blood cancers that have not responded to standard treatments. The goal is to see if it can shrink or control the cancer.
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
This Phase 1 trial tests LMY-920 in people with multiple myeloma that has returned or stopped responding after multiple standard therapies. It’s meant to see if the treatment can work and to better understand its safety and side effects in this situation.
This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.
This Phase 1 study tests a new immune cell treatment (BAFF CAR-T) for people with non-Hodgkin lymphoma that has come back or did not respond well to treatment. It aims to see how safe it is and whether it can help control the lymphoma.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BAFFR on B-cell blood cancers. The goal is to see if it can shrink tumors when given after a short chemotherapy course to prepare the body.
Hear when a new Non-Hodgkin Lymphoma Refractory/ Relapsed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.